Bahija Jallal (file photo)
January 11, 2021 09:25 AM EST
Financing

Hot on the heels of a pos­i­tive PhI­II, Im­muno­core hauls in $175M as it hunts its first TCR OK

John Carroll

Editor & Founder

Six weeks af­ter Bahi­ja Jal­lal’s crew at TCR pi­o­neer Im­muno­core rolled out an up­beat pre­sen­ta­tion on their lead drug’s in­ter­im Phase III da­ta, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times